Stay updated with breaking news from Michael Blaha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.
Similar to secondhand cigarette smoke, this exposure is being labelled an 'invisible threat' by scientists.
A REDUCE-IT analysis highlights consistent cardiovascular benefits with icosapent ethyl across varying levels of Lp(a).
At NYFW, models hit the runway in power suits toting a cigarette between their fingers, signaling a possible resurgence of smoking, despite years of health advisories and campaigns against big tobacco.
Universal risk predictor for cardiovascular disease, suitable for use in both primary and secondary prevention, would streamline risk assessmentÂ